Tolerogenic nanoparticles induce type II collagen-specific regulatory T cells and ameliorate osteoarthritis

Sci Adv. 2022 Nov 25;8(47):eabo5284. doi: 10.1126/sciadv.abo5284. Epub 2022 Nov 25.

Abstract

Local inflammation in the joint is considered to contribute to osteoarthritis (OA) progression. Here, we describe an immunomodulating nanoparticle for OA treatment. Intradermal injection of lipid nanoparticles (LNPs) loaded with type II collagen (Col II) and rapamycin (LNP-Col II-R) into OA mice effectively induced Col II-specific anti-inflammatory regulatory T cells, substantially increased anti-inflammatory cytokine expression, and reduced inflammatory immune cells and proinflammatory cytokine expression in the joints. Consequently, LNP-Col II-R injection inhibited chondrocyte apoptosis and cartilage matrix degradation and relieved pain, while injection of LNPs loaded with a control peptide and rapamycin did not induce these events. Adoptive transfer of CD4+CD25+ T cells isolated from LNP-Col II-R-injected mice suggested that Tregs induced by LNP-Col II-R injection were likely responsible for the therapeutic effects. Collectively, this study suggests nanoparticle-mediated immunomodulation in the joint as a simple and effective treatment for OA.

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Collagen Type II / adverse effects
  • Cytokines / metabolism
  • Mice
  • Nanoparticles*
  • Osteoarthritis* / metabolism
  • Osteoarthritis* / therapy
  • Sirolimus / pharmacology
  • T-Lymphocytes, Regulatory / metabolism

Substances

  • Collagen Type II
  • Lipid Nanoparticles
  • Cytokines
  • Anti-Inflammatory Agents
  • Sirolimus